Combining Immunotherapies With Targeted Therapies and Other Immunotherapies

Lurbinectedin yielded a value of 6.52 nM on the key pharmacological efficacy variable IC50, according to a poster presented at the 2023 Annual Meeting of the American Association for Cancer Research

Jason Luke, MD, leads a discussion with Sandip Patel, MD, about the present and future of immunotherapy in cancer.

Joyce O’Shaughnessy, MD, highlights advances in breast cancer management which will be presented at an upcoming medical meeting.

Amivantamab elicited an objective response rate of 37% per investigator assessment, with a median duration of response of 12.5 months, according to long-term data from the CHRYSALIS trial.

A number of novel immunotherapies, such as PD-1 inhibitors and targeted drug therapies with BRAF and MEK inhibitors, have become available for managing advanced melanoma.

Today, we are in the heyday of biomarker discovery, utilization, and translation to clinical practice.